Detailansicht

Wissensnetz

Person

Michael Rassner

Name	Michael Rassner
Ort	Freiburg im Breisgau (Geburtsort) Deutschland
Akademischer Grad bzw. Titel	Dr. med.
Variante	Michael Philipp Rassner
Beziehung	Medizin (Studienfach)
Weitere Angaben	Diss. 2015, Universität Freiburg, Medizinische Fakultät
Datensatztyp	Person
GND-Nummer	1074438930
Datensatz-ID	1074438930
Beteiligt an alle anzeigen ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease Development of highly sensitive digital droplet PCR for detection of cKIT mutations in circulating free DNA that mediate resistance to TKI treatment for gastrointestinal stromal tumor (GIST) Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers The esthetic outcome of recipient sites of gracilis muscle flaps versus anterolateral thigh flaps : : a retrospective study Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures Murine oncostatin M has opposing effects on the proliferation of OP9 bone marrow stromal cells and NIH/3T3 fibroblasts signaling through the OSMR Ten color multiparameter flow cytometry in bone marrow and apheresis products for assessment and outcome prediction in multiple myeloma patients Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML Dapsone-induced hemolytic anemia in multiple myeloma: case report of various differential diagnoses Personalized treatment selection and disease monitoring using circulating tumor DNA profiling in real-world cancer patient management Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small cell lung cancer Antiepileptika-Effekte in vitro und in vivo

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Michael Rassner

ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease

Development of highly sensitive digital droplet PCR for detection of cKIT mutations in circulating free DNA that mediate resistance to TKI treatment for gastrointestinal stromal tumor (GIST)

Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers

The esthetic outcome of recipient sites of gracilis muscle flaps versus anterolateral thigh flaps : : a retrospective study

Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers

Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma

Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma

Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures

Murine oncostatin M has opposing effects on the proliferation of OP9 bone marrow stromal cells and NIH/3T3 fibroblasts signaling through the OSMR

Ten color multiparameter flow cytometry in bone marrow and apheresis products for assessment and outcome prediction in multiple myeloma patients

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab

CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML

Dapsone-induced hemolytic anemia in multiple myeloma: case report of various differential diagnoses

Personalized treatment selection and disease monitoring using circulating tumor DNA profiling in real-world cancer patient management

Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small cell lung cancer

Antiepileptika-Effekte in vitro und in vivo